Aarti Pharmalabs: Should You Buy, Hold, or Sell Right Now?
- September 4, 2026
- Posted by: Lakshit Sharma
- Category: Market
Aarti Pharmalabs share price Rs 874 (NSE), roughly flat today. 52-week range Rs 585 to Rs 946.10. Q1 FY27 revenue up 38.3% YoY, profit up 53.8% YoY.
Quick Answer
Aarti Pharmalabs Ltd share price is trading around Rs 874, roughly 8 percent below its 52-week high of Rs 946.10 but well above its 52-week low of Rs 585. Q1 FY27 revenue grew a strong 38.3 percent year on year to Rs 536.25 crore, with net profit up 53.8 percent to Rs 76.14 crore, continuing consistent growth for this pharma intermediates and API manufacturer, which was spun off from Aarti Industries. Full-year FY25 profit grew 25.6 percent to Rs 272.4 crore. The stock trades at 36.8 times earnings, roughly in line with the pharma sector average near 38 times.
Aarti Pharmalabs share price is trading close to its 52-week high of Rs 946.10, with Aarti Pharmalabs share price near Rs 874 on the NSE, well above its 52-week low of Rs 585. With strong growth in Q1 FY27, investors are asking whether this pharma intermediates manufacturer is a stock to buy near its highs, a hold, or a sell.
This Aarti Pharmalabs stock analysis walks through the Q1 FY27 numbers, valuation against the pharma sector, shareholding pattern and the technical setup, using figures sourced from company disclosures and public filings.
Click Here – Get Free Investment Predictions
About Aarti Pharmalabs
Before deciding on Aarti Pharmalabs share price, it helps to understand the underlying business. Aarti Pharmalabs Ltd. manufactures pharmaceutical intermediates and active pharmaceutical ingredients, including xanthine derivatives and other specialty pharma chemicals, having been demerged from Aarti Industries to operate as a standalone, separately listed pharma-focused entity.
As a focused pharma intermediates and API manufacturer, Aarti Pharmalabs benefits from consistent global demand for its specialty pharmaceutical chemical products, alongside continued capacity investments supporting its growth trajectory.
Aarti Pharmalabs Share Price Today: Key Levels
The table below summarises where Aarti Pharmalabs share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Aarti Pharmalabs CMP (NSE) | Rs 874.00 |
| Aarti Pharmalabs CMP (BSE) | Rs 873.40 |
| 52-Week High | Rs 946.10 |
| 52-Week Low | Rs 585.00 |
| Market Capitalisation | Approximately Rs 7,852 crore |
Aarti Pharmalabs share price is trading close to its 52-week high, having risen substantially from its 52-week low, reflecting sustained investor confidence in this pharma intermediates manufacturer’s growth trajectory.
Check the Univest Screener for Live Stock Data
Aarti Pharmalabs Financial Performance
The Aarti Pharmalabs share price trend is closely tied to how these numbers evolve each quarter. Aarti Pharmalabs reported Q1 FY27 (June 2026 quarter) revenue of Rs 536.25 crore, up 38.3 percent year on year from Rs 387.79 crore, with net profit growing 53.8 percent year on year to Rs 76.14 crore from Rs 49.5 crore. This continued a consistent sequential growth trend across recent quarters.
For the full year FY25, the company reported revenue of Rs 2,125.19 crore, up 14.4 percent year on year, with net profit of Rs 272.4 crore, up 25.6 percent, confirming the growth trend has been sustained over a full year.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Q1 FY27 (Jun 2026) | Rs 536.25 crore | Rs 76.14 crore | +38.3% revenue, +53.8% profit YoY |
| FY25 (full year) | Rs 2,125.19 crore | Rs 272.40 crore | +14.4% revenue, +25.6% profit YoY |
Valuation Check: Is Aarti Pharmalabs Share Price Expensive?
Any view on Aarti Pharmalabs share price should start from these valuation multiples. Aarti Pharmalabs share price currently reflects a price to earnings ratio of about 36.8 times trailing earnings, roughly in line with the broader pharma sector average of about 38 times. The price to book ratio stands near 3.7 times, with return on equity at 8.22 percent.
Debt to equity of 0.36 is moderate. Historically, focused pharma intermediates manufacturers with consistent growth have traded near sector-average multiples, consistent with the current market assessment of Aarti Pharmalabs’ steady execution since its demerger.
Technical Signals: What the Chart Shows
Price action here often foreshadows the next move in Aarti Pharmalabs share price. Aarti Pharmalabs share price is currently positioned about 8 percent below its 52-week high of Rs 946.10 and roughly 49 percent above its 52-week low of Rs 585, reflecting a strong overall run over the past year. A stock trading this close to its high, backed by accelerating growth, typically signals the market rewarding tangible execution.
Trading volumes remain moderate, so investors should track Aarti Pharmalabs share price alongside capacity expansion progress and global pharma intermediates demand trends in coming quarters, rather than reacting to any single day’s move at these technical levels.
Download the Univest iOS App or Univest Android App to track Aarti Pharmalabs’ live price and technical levels.
Shareholding Pattern
Shifts here can influence Aarti Pharmalabs share price more than headline news on some sessions. Aarti Pharmalabs was demerged from Aarti Industries to operate as a standalone, separately listed pharma-focused entity. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company’s latest exchange filing.
Why Investors Are Watching Aarti Pharmalabs
- Strong and accelerating growth: Q1 FY27 profit growth of 53.8 percent outpaced the already solid full-year FY25 growth of 25.6 percent.
- Focused pharma intermediates strategy: As a standalone entity following its demerger from Aarti Industries, the company can pursue a dedicated pharma-focused growth strategy.
- Roughly in-line valuation: A 36.8x PE close to the sector average reflects a fair market assessment of the company’s consistent execution.
- Established xanthine derivatives franchise: The company’s specialty pharma chemical products, including xanthine derivatives, provide a differentiated position in global pharma intermediates supply chains.
Risks and Factors to Watch
- Pharma intermediates sector cyclicality: As a pharma intermediates manufacturer, Aarti Pharmalabs’ revenue is exposed to global pharmaceutical demand and pricing cycles.
- Capacity expansion execution risk: Continued growth depends on successful execution of capacity investments, which carries typical project execution risk.
- Competitive pharma intermediates market: Aarti Pharmalabs competes against other domestic and global pharma intermediates and API manufacturers.
- Currency and export market sensitivity: With significant global demand exposure, results can be affected by currency fluctuations and international pharma market cycles.
Aarti Pharmalabs Share Price Target: What the Data Suggests
Until then, Aarti Pharmalabs share price remains best tracked through live, verified data rather than a single fixed number. Aarti Pharmalabs does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company delivering strong, accelerating growth, trading roughly in line with the pharma sector.
Historically, focused pharma intermediates manufacturers have sustained solid valuations reflecting consistent execution. Investors who want live, updated research can check the Univest Screener, and should consult a SEBI-registered investment adviser for guidance tailored to their own goals.
Aarti Pharmalabs: Should You Buy, Hold, or Sell Right Now?
This is the core question behind Aarti Pharmalabs share price right now. The Aarti Pharmalabs buy or sell decision depends on whether you believe the current growth pace can be sustained.
The case for buying: Investors who see the strong, accelerating growth and focused pharma intermediates strategy as attractive may find the stock’s proximity to its 52-week high justified by fundamentals.
The case for holding: Existing shareholders who already track Aarti Pharmalabs’ execution since its demerger may prefer to stay invested.
The case for trimming or waiting: Investors wanting a valuation discount to the sector before committing fresh capital may prefer to wait for a more attractive entry point.
Historically, focused pharma intermediates manufacturers have rewarded patient investors, so weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.
Conclusion
Aarti Pharmalabs share price reflects a focused pharma intermediates manufacturer delivering strong, accelerating growth in Q1 FY27, trading close to its 52-week high at a valuation roughly in line with the pharma sector. Whether that makes the stock a buy, a hold or a sell right now depends on whether this growth pace can be sustained. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is Aarti Pharmalabs a good stock to buy right now?
Ans. Aarti Pharmalabs grew Q1 FY27 revenue 38.3 percent and profit 53.8 percent year on year, continuing an accelerating trend also seen in FY25. The stock trades roughly in line with the pharma sector, which may appeal to investors who value this consistent execution.
Q2. What is the Aarti Pharmalabs share price today?
Ans. Aarti Pharmalabs share price is trading around Rs 874 on the NSE, close to its 52-week high of Rs 946.10. The stock’s 52-week low is Rs 585.
Q3. What is the Aarti Pharmalabs share price target?
Ans. Aarti Pharmalabs does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser.
Q4. What does Aarti Pharmalabs manufacture?
Ans. Aarti Pharmalabs manufactures pharmaceutical intermediates and active pharmaceutical ingredients, including xanthine derivatives and other specialty pharma chemicals.
Q5. Was Aarti Pharmalabs demerged from Aarti Industries?
Ans. Yes, Aarti Pharmalabs was demerged from Aarti Industries to operate as a standalone, separately listed pharma-focused entity.
Q6. What is Aarti Pharmalabs’ market capitalisation and PE ratio?
Ans. Aarti Pharmalabs has a market capitalisation of approximately Rs 7,852 crore and trades at a price to earnings ratio of about 36.8 times, roughly in line with the pharma sector average PE of about 38 times.